The vaccine is administered using Inovio Biomedical’s technology called the MedPulser gene delivery system.
The research showed that in comparison with the gene gun delivery the MedPulser gene delivery system performed as good as or better than the gene gun in inducing immune responses capable of clearing liver cells expressing hepatitis C virus proteins.
These data were obtained in support of a planned application for a clinical trial designed to test the therapeutic use of the combination of the ChronVac-C DNA vaccine and Inovio’s MedPulser gene delivery system in chronic hepatitis C infections.
Tripep intends to conduct this phase I clinical study with healthy volunteers in Sweden in the first half of 2007.